A phase I/II clinical trial reported the possibility of expanding AFP-specific CD8 T cell response in advanced HCC patients with high circulating levels of AFP after immunization with AFP peptide-pulsed autologous dendritic cells [47]. This evidence concerns the gene CD8A and hepatocellular carcinoma.